Research in Stroke

AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke. (ARCADIA)

[Funded by: NINDS]

Summary: The objective of this study is to determine if apixaban is superior to aspirin for prevention of recurrent stroke in patients with embolic stroke of undetermined source (ESUS) and atrial cardiopathy.

Key Inclusion Criteria:

  • Age ≥ 45 years
  • Clinical diagnosis of ischemic stroke + brain imaging to rule out hemorrhagic stroke
  • mRS ≤ 4
  • Randomization within 3 – 180 days post stroke onset
  • ESUS

Atrial cardiopathy defined as ≥1 marker (determined by central coordinating center after consent)

This study is also on www.clinicaltrials.gov. Once you access this page, look for identifier: NCT03192215

 

Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2)

Site Principal Investigator: Wei Zhou

[Funded by: NINDS]

Summary: The objective of this study is to perform two parallel trials for asymptomatic carotid stenosis to determine 1) treatment differences between intensive medical management vs. CEA plus intensive medical management, and 2) treatment differences between intensive medical management vs. carotid angioplasty and stenting plus intensive medical management.

 Key Inclusion Criteria:

  • Age ≥ 35
  • Carotid stenosis ≥70% (catheter angiography or DUS with secondary confirmation)
  • No hx stroke or TIA ipsilateral to stenosis within 180 days
  • mRS ≤ 1

 

Sleep for Stroke Management And Recovery Trials (Sleep SMART)

[Funded by: NINDS]

Summary: The objective of this study is to test whether treatment of obstructive sleep apnea (OSA) with aCPAP after recent stroke or high-risk TIA prevents recurrent stroke, acute coronary syndrome, or death.

 Key Inclusion Criteria:

  • Age ≥ 18
  • TIA with ABCD2 ≥ 4 or ischemic stroke within the prior 14 days

 

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction (CHARM)

[Study Sponsor: Biogen]

Summary: The primary objective of this study is to determine if BIIB093 improves functional outcome at Day 90 as measured by the modified Rankin Scale (mRS) when compared with placebo in subjects with large hemispheric infarction (LHI).

 Key Inclusion Criteria:

  • Age 18-70
  • Ischemic stroke in MCA territory
  • Screening NIHSS ≥ 10
  • Premorbid mRS ≤ 2
  • Large hemispheric infarct 80-300 cc on DWI or CTP or ASPECTS 1-5
  • Study drug can be administered < 10 hours from LKW
  • Decompressive craniectomy NOT planned

 Study Drug Administration: 72-hour continuous infusion

 This study is also on www.clinicaltrials.gov. Once you access this page, look for identifier: NCT02864953

 

Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery (ASPIRE)

[Funded by: NINDS]

Summary: The objective of this study is to determine if apixaban is superior to aspirin for prevention of recurrent stroke in patients with recent intracerebral hemorrhage (ICH) and high-risk non-valvular atrial fibrillation.

Key Inclusion Criteria:

  • Age ≥ 18
  • ICH confirmed by CT or MRI
  • Non-valvular atrial fibrillation or atrial flutter
  • CHA2DS2-VASc score ≥ 2
  • Randomization within 14 – 180 days post stroke

 

StATins Use in intRacerebral hemorrhage patieNts (SATURN)

[Funded by: NINDS]

Summary: The objective of this study is to determine the effects of continuation vs. discontinuation of statins on the risk of intracerebral hemorrhage (ICH) recurrence during 24 months of follow-up in patients presenting with a spontaneous lobar ICH while taking a statin drug.

Key Inclusion Criteria:

  • Age ≥ 50 years.
  • Spontaneous lobar ICH confirmed by CT or MRI
  • Patient was taking a statin drug at the onset of the qualifying/index ICH
  • Randomization within 7 days of the onset of the qualifying ICH

 

For questions regarding the above studies, please contact:

 

University of Arizona, Health Sciences, Department of Neurology
1501 N. Campbell Avenue
Tucson, AZ 85724